Tag:
cervical cancer
Latest Headlines
Latest Headlines
Study examines cost-effectiveness of Gardasil
A new study in the New England Journal of Medicine questions the cost-effectiveness of Gardasil in older women, saying that the payback is reduced by their increased exposure to the virus that causes
ALSO NOTED: GSK releases new Cervarix data; FDA mulls DTC ads; and much more...
> GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of
SPOTLIGHT: Sysmex, Matritech end pact
Sysmex and Matritech have dissolved a 2002 agreement under which Sysmex was granted a license for the use of Matritech's NMP 179 cervical cancer technology. Matritech, which is focused on
ALSO NOTED: New constipation data; GSK touts Cervarix study; Spherix transitions to biotech; and much more...
> Wyeth and Progenics say that a three-month extended study of their constipation therapy produced positive data. Release > GlaxoSmithKline says that the biggest study yet has produced impressive data on the effectiveness of Cervarix in preventing cervical cancer. It will need plenty of powerful data if it intends to grab market share from Gardasil. …
Press Release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
Press Release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
ALSO NOTED: Emisphere fires CEO; Crucell in new antibody pact; Watson touts Phase III results; and much more...
> Chutes & Ladders: Emisphere Technologies has fired its chairman and CEO, Dr. Michael Goldberg, without citing a reason for his dismissal. Lewis Bender, senior vice president of business development, takes over in the interim. Report > Crucell has inked a development deal with Novo Nordisk to develop new antibodies. …
Merck's McGlynn has key role developing vaccines
BusinessWeek profiles Margaret McGlynn (photo), president of Merck Vaccines for the past 14 months. During that time, Merck has launched four vaccines, including Gardasil as a protection against cervical cancer. These vaccines are at the center of Merck's plans to revive the company from its post-Vioxx debacle. Gardasil alone is expected to generate $2 billion to $4 billion in annual revenue.- here's the …
ALSO NOTED: Glaxo wins approval for Hycamtin; Affymax forecasts share price;The best (and worst) biotech stocks of 2006; and mu
> President Bush has signed a new law that expands the powers of federal authorities targeting the activities of animal rights groups. Report > GlaxoSmithKline has won EMEA approval to market Hycamtin, a combinatorial therapy for cervical cancer. Report > Affymax has …
ALSO NOTED: Emisphere shares dive on Phase II data; NovImmune raises $46M;and much more...
> Shares of Emisphere Technologies took a nasty hit today after the company reported negative Phase II data from a diabetes study. Report > Switzerland's NovImmune raised $46 million in its second round of financing. …
VC: Morphotek lands $40M VC round
Morphotek lands $40M VC round
